NCT06976658

Glucokinase Activator in Monogenic Diabetes

Evaluating a Novel, Allosteric Glucokinase Activator in Monogenic Diabetes Secondary to Inactivating Glucokinase Mutations: a Randomised, Cross-over Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Chinese University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial

Detailed description

Evaluating a novel, allosteric glucokinase activator in monogenic diabetes secondary to inactivating glucokinase mutations: a randomised, cross-over trial

Conditions

• Diabetes Mellitus
• Monogenic Diabetes

Interventions

Type	Name	Description
DRUG	Dorzagliatin	Dorzagliatin 50mg bd
DRUG	matched placebo	matched placebo

Timeline

• Start date: 2025-05-28
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-05-16
• Last updated: 2025-05-16

Locations

1 site across 1 country: Hong Kong